Insider buying last 90 days
No open-market insider purchases were filed for TNGX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every TNGX insider filing, plotted on the chart in Gekko.Open TNGX in Gekko
NASDAQ: TNGX
Tango Therapeutics (TNGX) Stock Analysis & Forecast
Oct 12 close
$24.17+0.36 (+1.5%)
Gekko Brief
AI summaryOct 12 closeThis week's news flow centers on insider activity and analyst commentary rather than company fundamentals. Multiple Form 4 filings disclosed that Adam Crystal, President of R&D at Tango Therapeutics, sold 27,000 shares for $660,796 on October 1, after exercising options at $5.20 per share, under a pre-arranged Rule 10b5-1 trading plan; a separate filing noted insider Dario Palmieri sold 117,162 shares at an average price of $5.64, totaling $660,796. Separately, analysts offered insights on Tango Therapeutics alongside peers Glaukos and Pfizer, with Tango Therapeutics carrying a Strong Buy consensus and a $42.57 average price target cited in that coverage.
TNGX closed at $24.17, up 1.5% on the day, sitting between its 50-day average of $24.46 and 200-day average of $21.38. The GekkoIndex reads 58.6, placing the stock in the Neutral zone, though the index has slipped 4.4 points over five sessions. Price remains 25% below Gekko Fair Value of $32.24.
The next earnings date falls on 3 November, 21 days out, within a typical 20-trading-day holding window; the prior quarter saw a loss of $0.37 per share against a $0.31 estimate, with a 5.8% reaction. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality over five years shows a 6.1% average 20-day return from this point, though gains occurred in only 2 of those years. Coverage includes 8 firms, with 7 rating the stock Buy and 1 Hold.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Tango Therapeutics price vs fair value
Close $24.17200-day averageGekko Fair Value $32.24
Tango Therapeutics quick facts
- Market cap
- $3.94B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$0.85
- Revenue, TTM
- $53.81M
- Profit margin
- -229.9%
- Dividend yield
- —
- Beta
- 1.17
- Volume
- 2.87M avg 3.53M
- 1-year return
- +230.2%
- Typical daily move
- ±6.2%
- Typical 20-day move
- ±15.1%
- 50-day average
- $24.46
- 200-day average
- $21.38
- Next earnings
- Nov 3
- Shares outstanding
- 168.6M
Tango Therapeutics swing-trade checklist
Tango Therapeutics scores 1 supportive, 3 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive3 mixed1 headwind
- Trendmixed
Averages disagree
Close $24.17 sits between the 50-day ($24.46) and 200-day ($21.38) averages, or the averages disagree.
See the chart - GekkoIndexmixed
58.6, Neutral
Reading 58.6 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
25.0% below
Price is 25% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 22 days
Reports on Nov 3, 2026, 22 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+6.1% on average
From this point in the calendar, the next 20 trading days averaged +6.1% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Tango Therapeutics stock chart and price history
Tango Therapeutics closed at $24.17 on Oct 12, 2026, +230.2% over the past year, inside a 52-week range of $6.69 to $34.39.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +1.6%
- 3 months
- −18.5%
- 6 months
- +12.1%
- 1 year
- +230.2%
The full TNGX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open TNGX in Gekko
Follow Tango Therapeutics through every session
Put TNGX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track TNGX in GekkoFree for 7 days. No credit card required.
About Tango Therapeutics
Tango Therapeutics works on medicines aimed at treating cancer, built around the idea of exploiting genetic weaknesses found in tumor cells. Its furthest-along candidate, TNG908, is a small molecule designed to block PRMT5, a protein enzyme, and is being studied as a treatment for cancers that carry MTAP gene deletions. The company is best known for this synthetic lethal approach, where a drug is matched to a specific genetic flaw in the cancer.
Beyond its lead program, Tango Therapeutics is developing a USP1 inhibitor meant for cancers with BRCA1 or BRCA2 mutations, along with an earlier-stage effort called Target 3 directed at STK11-mutant cancers. The company has a partnership with Gilead Sciences, Inc. through which the two work together on finding, developing, and bringing to market a range of cancer treatments.
Tango Therapeutics was founded in 2017 and is based in Cambridge, Massachusetts. Its shares are listed on the NASDAQ under the ticker TNGX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- tangotx.com
Tango Therapeutics GekkoIndex: the smart money zone
Tango Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 58.6, in the Neutral zone, down 4.4 points over five sessions.
58.6Neutral
Down 4.4 points over five sessions, from the Accumulation zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 54 | −4.4% | −12.2% | ||
| Accumulation | 238 | +0.9% | +4.5% | ||
| Neutral (current zone) | 340 | +2.4% | +10.9% | ||
| Distribution | 48 | +3.8% | +18.4% | ||
| Selling | 2 | Too few readings yet | |||
Average TNGX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the TNGX price, zone by zone.Track TNGX in Gekko
Is Tango Therapeutics stock overvalued? Gekko Fair Value
Tango Therapeutics trades 25.0% below Gekko Fair Value of $32.24, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Tango Therapeutics shares are worth, recalculated every trading day.
$32.24
Gekko Fair Value, Oct 10, 2026
25.0% Undervalued
At the end of Aug 2026 the price was 41.1% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open TNGX in Gekko
Tango Therapeutics insider and Congress trading
No open-market insider purchases were filed for Tango Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in TNGX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for TNGX, plotted on the chart in Gekko.Open TNGX in Gekko
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold TNGX.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Tango Therapeutics earnings: next date and track record
Tango Therapeutics reports on Nov 3, 2026 (22 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 3, 2026
22 days away
- EPS estimate
- −$0.35
- Revenue estimate
- $3.28M
4 of 8reports beat the EPS estimate
±17%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | −$0.37 est −$0.31 | — | +5.8% |
| May 13, 2026 | −$0.32 est −$0.30 | — est $578K | +5.8% |
| Mar 5, 2026 | −$0.29 est −$0.32 | — est $500K | +37.2% |
| Nov 4, 2025 | $0.13 est $0.01 | $53.81M est $556K | −6.2% |
| Aug 5, 2025 | −$0.35 est −$0.35 | $3.18M est $6.41M | −1.4% |
| May 12, 2025 | −$0.36 est −$0.35 | $5.39M est $6.36M | +22.8% |
| Feb 27, 2025 | −$0.34 est −$0.34 | $4.12M est $8.02M | −11.2% |
| Nov 6, 2024 | −$0.27 est −$0.37 | $11.61M est $8.02M | −45.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Tango Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Tango Therapeutics is $45.18, +86.9% from the last close, from 8 firms rating the stock in the last 90 days.
$45.18consensus 12-month target, +86.9% from the last close
Now $24.17Avg $45.18
Low $24High $68
Each firm’s latest rating in the last 90 days: 8 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 12 | Canaccord Genuity | $46 | +90.3% |
| Oct 8 | Canaccord Genuity | $46 | +90.3% |
| Oct 1 | Piper Sandler | $24 | −0.7% |
| Sep 24 | Canaccord Genuity | $46 | +90.3% |
| Sep 24 | Guggenheim | $35 | +44.8% |
+10.9%average 20-day move after past Neutral readings
+6.1%average move over the next 20 trading days in the last 5 years
±6.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Tango Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Tango Therapeutics averaged +6.1% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +10.1% | 3 of 5 |
| Next 10 trading days | +9.8% | 2 of 5 |
| Next 15 trading days | +15.4% | 2 of 5 |
| Next 20 trading days | +6.1% | 2 of 5 |
| Next 30 trading days | +7.7% | 2 of 5 |
For scale, TNGX’s typical 20-trading-day move in either direction is about 15.1%.
Tango Therapeutics market cap and key statistics
Tango Therapeutics’s market cap is $3.94B and revenue of $53.81M over the last twelve months.
Valuation
- Market cap
- $3.94B
- EPS, TTM
- −$0.85
- Gekko Fair Value
- $32.24
Trading
- Volume
- 2.87M
- Avg volume, 20 days
- 3.53M
- 52-week high
- $34.39
- 52-week low
- $6.69
- Shares outstanding
- 168.6M
Financials
- Revenue, TTM
- $53.81M
- Profit margin
- -229.9%
- Return on equity
- -21.3%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.17
- Typical daily move
- ±6.2%
- Typical 20-day move
- ±15.1%
Tango Therapeutics stock news this week
Coverage of Tango Therapeutics this week reads neutral: 1 positive, 4 neutral and 2 negative headlines.
- Tango Therapeutics R&D president Adam Crystal sells $660,796 in shares By Investing.comInvesting.com Canada, Oct 12
- Form 4 Tango Therapeutics Inc For: 11 October By Investing.comInvesting.com UK, Oct 12
- Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Glaukos (GKOS) and Pfizer (PFE)The Globe and Mail, Oct 9
- Tango therapeutics R&D president Adam Crystal sells $660k in shares.Investing.com Canada, Oct 6
- Tango Therapeutics Insider Sold Shares Worth $660,796, According to a Recent SEC FilingMoomoo, Oct 6
- Tango Therapeutics (NASDAQ:TNGX) vs. Alumis (NASDAQ:ALMS) Financial AnalysisDefense World, Oct 6
Tango Therapeutics peers
Tango Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Tango Therapeutics stock FAQ
What is Tango Therapeutics’s market cap?
Tango Therapeutics’s market cap is $3.94B at the Oct 12, 2026 close of $24.17, with 168.6M shares outstanding.
What is the Tango Therapeutics stock forecast?
The consensus analyst 12-month price target for Tango Therapeutics is $45.18, +86.9% from the last close. Of the 8 firms that rated the stock in the last 90 days, 7 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Tango Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Tango Therapeutics is undervalued: the Oct 12, 2026 close of $24.17 is 25.0% below Gekko Fair Value of $32.24. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Tango Therapeutics report earnings next?
Tango Therapeutics is expected to report on Nov 3, 2026 (22 days away). Analysts expect earnings of −$0.35 per share on revenue of $3.28M. Tango Therapeutics beat the earnings estimate in 4 of its last 8 reports, moving 17% on average across the report.
What is Tango Therapeutics’s 52-week high and low?
Tango Therapeutics’s 52-week high is $34.39 and its 52-week low is $6.69; it closed at $24.17 on Oct 12, 2026, +230.2% over the past year.
Is Tango Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 5 items with data read as supportive (fair value), 3 as mixed (trend, gekkoindex and seasonality) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Tango Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.